Premium
Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study
Author(s) -
Fowler N.,
Gopal A.K.,
Schuster S.J.,
Trotman J.,
Hess G.,
Hou J.,
Yacoub A.,
Lill M.,
Martin P.,
Vitolo U.,
Spencer A.,
Radford J.,
Jurczak W.,
Morton J.,
Osmanov D.,
Caballero D.,
Deshpande S.,
Vermeulen J.,
Damle R.,
Schaffer M.,
Balasubramanian S.,
Cheson B.,
Salles G.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_75
Subject(s) - medicine , follicular lymphoma , lymphoma , gastroenterology , regimen , phases of clinical research , flow cytometry , oncology , immunology , toxicity